This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tilade

Pfizer Inc.

Drug Names(s): Nedocromil

Description: Tilade inhibits the activation of and mediator release from a variety of inflammatory cells, including: mast cells, eosinophils, neutrophils, macrophages, monocytes, and platelets. Tilade is delivered via a metered dose inhaler.

Deal Structure: On December 30, 2002, King licensed or acquired the rights to three branded pharmaceutical products from Aventis for the initial cash payment of $197.5 million, plus $3.8 million of expenses. This included rights in the United States, Puerto Rico, and Canada to Intal and Tilade, inhaled anti-inflammatory agents for the management of asthma.

In October 2010, Pfizer and King Pharmaceuticals announced that they have entered into a definitive merger agreement. In February 2011, Pfizer completed its acquisition of King.

Partners: Sanofi


Tilade News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug